<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03820401</url>
  </required_header>
  <id_info>
    <org_study_id>UGent_FiberClotting_1</org_study_id>
    <nct_id>NCT03820401</nct_id>
  </id_info>
  <brief_title>Dialysis Performance of Different Dialyzer Membranes Using Different Coagulation Strategies</brief_title>
  <official_title>Quantification of Dialysis Performance of Different Dialyzer Membranes With Different Coagulation Strategies, Using a Reference microCT Scanning Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coagulation within the dialyzer membrane fibres is an obvious biological sign of&#xD;
      bio-incompatibility. To avoid clotting during extracorporeal treatment, an anticoagulant is&#xD;
      added to the circuit, resulting in an increased risk for bleeding complications.&#xD;
&#xD;
      In addition, there is evidence that a substantial number of fibers can become blocked before&#xD;
      this is reflected in routinely observed parameters, or in termination of the dialysis&#xD;
      session. Little is known about the impact of such subclinical clotting on dialyzer&#xD;
      performance in terms of solute clearance.&#xD;
&#xD;
      Membrane clogging due to deposition of proteins and red blood cells on the dialysis membrane&#xD;
      may influence both the diffusive and convective transport characteristics of the dialyzer&#xD;
      membrane before leading to complete dialyzer clotting.&#xD;
&#xD;
      In 2018, the invesitgators described a method to objectively count the number of blocked&#xD;
      fibres inside a dialyzer using a micro-CT scanning technique.&#xD;
&#xD;
      In the present trial, the investigators use this method to assess the resistance of the&#xD;
      dialyzer to clotting, and to evaluate the impact of subclinical fibre blocking on solute&#xD;
      removal and thus performance of a dialyzer during a dialysis session.&#xD;
&#xD;
      The aim of this randomized cross-over study is to objectively quantify the performance of&#xD;
      different dialyzer membranes: ATA™ membrane in the Solacea™ dialyzer, polysulfone membrane in&#xD;
      the FX800 dialyzer, and the heparin-coated AN membrane in the Evodial dialyzer, and this with&#xD;
      different anticoagulation strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single centre, randomized cross-over study includes ten consecutive stable chronic&#xD;
      hemodialysis (HD) patients who experienced stable dialysis sessions during the last 4 weeks,&#xD;
      and had no known coagulation disorder, active inflammation or malignancy.&#xD;
&#xD;
      Double-needle vascular access is achieved through a native arterio-venous fistula or a&#xD;
      well-functioning double lumen tunnelled central venous catheter.&#xD;
&#xD;
      In a first test series, each patient is dialyzed for 240min (at midweek) in 4 different&#xD;
      regimens, randomly using 2 different dialyzers and 2 different anticoagulation schemes.&#xD;
      Patients receive their regular brand of Low-Molecular-Weight Heparin anticoagulation at the&#xD;
      beginning of the dialysis session, and this randomly either at their regular dose (full dose&#xD;
      1/1) or at only 50% of their regular dose (half dose 1/2). All test sessions are performed&#xD;
      with blood flow at 300mL/min and dialysate flow at 500mL/min in post dilution&#xD;
      hemodiafiltration (HDF) mode (substitution flow 75mL/min). Ultrafiltration rates is set&#xD;
      according to the patient's interdialytic weight gain and clinical status:&#xD;
&#xD;
        1. ATA™ Solacea 19H - HDF - 1/1 anticoagulation&#xD;
&#xD;
        2. ATA™ Solacea 19H - HDF - 1/2 anticoagulation&#xD;
&#xD;
        3. polysulfone FX800 - HDF - 1/1 anticoagulation&#xD;
&#xD;
        4. polysulfone FX800 - HDF - 1/2 anticoagulation&#xD;
&#xD;
      During the 4 experimental midweek sessions, blood is sampled from the arterial and venous&#xD;
      blood lines, and spent dialysate is sampled from the outlet line, all at 60min after the&#xD;
      dialysis start. Blood samples are immediately centrifuged and serum and dialysate are stored&#xD;
      at -80°C until batch analysis.&#xD;
&#xD;
      Concentrations of urea, kappa and lambda free light chains, and myoglobin are determined.&#xD;
      Extraction ratios and adsorption on the membrane are calculated from concentrations.&#xD;
&#xD;
      At the end of the dialysis session, a standard rinsing procedure of the hemodialyzer is&#xD;
      performed using exact 300mL rinsing solution. Next, the hemodialyzer is dried using&#xD;
      continuous positive pressure ventilation. Dialyzer fibre blocking is visualized in the&#xD;
      dialyzer outlet potting using a 3D CT scanning technique on micrometer resolution. HECTOR is&#xD;
      a High Energy CT scanner Optimized for Research, built by the Ghent University Centre for&#xD;
      X-ray Tomography (UGCT) in collaboration with the UGCT spin-off company XRE (Gent, Belgium).&#xD;
      In front of the X-ray source, the dialyzer is mounted vertically on a precision rotation&#xD;
      stage, and radiographies were recorded over 360° with an angular interval of 0.15°. Scan&#xD;
      conditions are optimized to maximize the signal-to-noise ratio based on the sample size and&#xD;
      structure, and the scanner properties. The tube voltage is set at 80kV, at a power of 20&#xD;
      Watts, the maximal power that allowed imaging at a resolution of 25µm. A total of 2401&#xD;
      projections are recorded with 500ms exposure each, resulting in a total exposure time of 20&#xD;
      minutes. Acquired images at 0 (projection 1) and 360° (projection 2401) are compared to&#xD;
      exclude movement of the hemodialyzer during the scanning process. Reconstruction of the raw&#xD;
      projection data is performed with the Octopus Reconstruction software package, licensed by&#xD;
      XRE23.&#xD;
&#xD;
      Fibers are counted in the central cross-section of the dialyzer outlet potting in a&#xD;
      computer-based way using the Fiji image processing toolkit of ImageJ analysis software&#xD;
      (ImageJ 1.51H, NIH, Bethesda, USA), an open-source platform for biological-image analysis.&#xD;
&#xD;
      In a second test series in 10 stable HD patients, no blood sampling is performed but&#xD;
      dialyzers are scanned post dialysis. The following different dialyzers in HD modus at midweek&#xD;
      are tested:&#xD;
&#xD;
        1. ATA™ Solacea 19H - HD - 1/1 anticoagulation&#xD;
&#xD;
        2. ATA™ Solacea 19H - HD - 1/2 anticoagulation&#xD;
&#xD;
        3. polysulfone FX800 - HD - 1/1 anticoagulation&#xD;
&#xD;
        4. polysulfone FX800 - HD - 1/2 anticoagulation&#xD;
&#xD;
        5. polysulfone FX800 - HD - 1/2 anticoagulation - with predialysis albmuin priming of the&#xD;
           membrane&#xD;
&#xD;
        6. Evodial - HD - no anticoagulation&#xD;
&#xD;
        7. Evodial - HD - no anticoagulation - with predialysis albmuin priming of the membrane&#xD;
&#xD;
      In a third test series in 10 stable HD patients, no blood sampling is performed but dialyzers&#xD;
      are scanned post dialysis. The following different dialyzers at midweek are tested:&#xD;
&#xD;
        1. ATA™ Solacea 19H - pre dilution HDF (substitution 150mL/min) - 1/4 anticoagulation&#xD;
&#xD;
        2. ATA™ Solacea 19H - post dilution HDF (substitution 75mL/min) - 1/4 anticoagulation&#xD;
&#xD;
        3. ATA™ Solacea 19H - HD - 1/4 anticoagulation&#xD;
&#xD;
        4. ATA™ Solacea 19H - pre dilution HDF (substitution 150mL/min) - no anticoagulation&#xD;
&#xD;
        5. ATA™ Solacea 19H - post dilution HDF (substitution 75mL/min) - no anticoagulation&#xD;
&#xD;
        6. ATA™ Solacea 19H - HD - no anticoagulation&#xD;
&#xD;
      First outcome measure: relative number of open fibers in each tested dialyzer. Second outcome&#xD;
      measure: dialyzer performance (extraction ratio, adsorption).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Actual">January 17, 2019</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of open fibres in the dialyzer</measure>
    <time_frame>17 weeks</time_frame>
    <description>Number of open fibres as assessed post dialysis by a reference microCT scanning technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extraction ratio of three middle molecules in the dialyzer</measure>
    <time_frame>4 weeks</time_frame>
    <description>Extraction ratio from myoglobin, kappa and lambda free light chains as calculated from their concentrations at the dialyzer inlet en outlet</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hemodialysis</condition>
  <condition>Coagulation</condition>
  <arm_group>
    <arm_group_label>Solacea_postHDF_1/1anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Solacea dialyzer (Nipro, Japan)&#xD;
choice of dialysis mode: post dilution hemodiafiltration&#xD;
choice of anticoagulation strategy: standard anticoagulation dose&#xD;
measurements:&#xD;
blood &amp; dialysate sampling at 60min after dialysis start&#xD;
microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_postHDF_1/2anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Solacea dialyzer (Nipro Japan)&#xD;
choice of dialysis mode: post dilution hemodiafiltration&#xD;
choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose&#xD;
measurements:&#xD;
blood &amp; dialysate sampling at 60min after dialysis start&#xD;
microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX800_postHDF_1/1anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)&#xD;
choice of dialysis mode: post dilution hemodiafiltration&#xD;
choice of anticoagulation strategy: standard anticoagulation dose&#xD;
measurements:&#xD;
blood &amp; dialysate sampling at 60min after dialysis start&#xD;
microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX800_postHDF_1/2anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)&#xD;
choice of dialysis mode: post dilution hemodiafiltration&#xD;
choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose&#xD;
measurements:&#xD;
blood &amp; dialysate sampling at 60min after dialysis start&#xD;
microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_HD_1/1anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Solacea dialyzer (Nipro, Japan)&#xD;
choice of dialysis mode: hemodialysis&#xD;
choice of anticoagulation strategy: standard anticoagulation dose&#xD;
measurement:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_HD_1/2anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Solacea dialyzer (Nipro, Japan)&#xD;
choice of dialysis mode: hemodialysis&#xD;
choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose&#xD;
measurements:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX800_HD_1/1anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)&#xD;
choice of dialysis mode: hemodialysis&#xD;
choice of anticoagulation strategy: standard anticoagulation dose&#xD;
measurements:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX800_HD_1/2anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)&#xD;
choice of dialysis mode: hemodialysis&#xD;
choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose&#xD;
measurements:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX800_HD_1/2anticoagulation_albuprime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)&#xD;
choice of dialysis mode: hemodialysis&#xD;
choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose&#xD;
preparation of dialyzer: the dialyzer was preprimed with albumin solution&#xD;
measurement:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evodial_HD_no anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Evodial 1.3 (Baxter, USA)&#xD;
choice of dialysis mode: hemodialysis&#xD;
choice of anticoagulation strategy: no anticoagulation is administered&#xD;
measurement:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evodial_HD_no anticoagulation_albuprime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Evodial 1.3 (Baxter, USA)&#xD;
choice of dialysis mode: hemodialysis&#xD;
choice of anticoagulation strategy: no anticoagulation is administered&#xD;
preparation of dialyzer: the dialyzer was preprimed with albumin solution&#xD;
measurement:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_preHDF_1/4anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Solacea dialyzer (Nipro Japan)&#xD;
choice of dialysis mode: pre dilution hemodiafiltration&#xD;
choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose&#xD;
measurements:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_postHDF_1/4anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Solacea dialyzer (Nipro Japan)&#xD;
choice of dialysis mode: post dilution hemodiafiltration&#xD;
choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose&#xD;
measurements:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_HD_1/4anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Solacea dialyzer (Nipro Japan)&#xD;
choice of dialysis mode: hemodialysis&#xD;
choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose&#xD;
measurements:microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_preHDF_no anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Solacea dialyzer (Nipro Japan)&#xD;
choice of dialysis mode: pre dilution hemodiafiltration&#xD;
choice of anticoagulation strategy: no anticoagulation is administered&#xD;
measurements:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_postHDF_no anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Solacea dialyzer (Nipro Japan)&#xD;
choice of dialysis mode: post dilution hemodiafiltration&#xD;
choice of anticoagulation strategy: no anticoagulation is administered&#xD;
measurements:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_HD_no anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention:&#xD;
choice of dialyzer: Solacea dialyzer (Nipro Japan)&#xD;
choice of dialysis mode: hemodialysis&#xD;
choice of anticoagulation strategy: no anticoagulation is administered&#xD;
measurements:&#xD;
- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>choice of dialyzer</intervention_name>
    <description>Fiber blocking is calculated in different commercially available dialyzers</description>
    <arm_group_label>Evodial_HD_no anticoagulation</arm_group_label>
    <arm_group_label>Evodial_HD_no anticoagulation_albuprime</arm_group_label>
    <arm_group_label>FX800_HD_1/1anticoagulation</arm_group_label>
    <arm_group_label>FX800_HD_1/2anticoagulation</arm_group_label>
    <arm_group_label>FX800_HD_1/2anticoagulation_albuprime</arm_group_label>
    <arm_group_label>FX800_postHDF_1/1anticoagulation</arm_group_label>
    <arm_group_label>FX800_postHDF_1/2anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_1/1anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_1/2anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_1/4anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_no anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_1/1anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_1/2anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_1/4anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_no anticoagulation</arm_group_label>
    <arm_group_label>Solacea_preHDF_1/4anticoagulation</arm_group_label>
    <arm_group_label>Solacea_preHDF_no anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>choice of dialysis mode</intervention_name>
    <description>Fiber blocking is calculated in different commercially available dialyzers used in different dialysis stategies</description>
    <arm_group_label>Evodial_HD_no anticoagulation</arm_group_label>
    <arm_group_label>Evodial_HD_no anticoagulation_albuprime</arm_group_label>
    <arm_group_label>FX800_HD_1/1anticoagulation</arm_group_label>
    <arm_group_label>FX800_HD_1/2anticoagulation</arm_group_label>
    <arm_group_label>FX800_HD_1/2anticoagulation_albuprime</arm_group_label>
    <arm_group_label>FX800_postHDF_1/1anticoagulation</arm_group_label>
    <arm_group_label>FX800_postHDF_1/2anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_1/1anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_1/2anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_1/4anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_no anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_1/1anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_1/2anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_1/4anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_no anticoagulation</arm_group_label>
    <arm_group_label>Solacea_preHDF_1/4anticoagulation</arm_group_label>
    <arm_group_label>Solacea_preHDF_no anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>choice of anticoagulation strategy</intervention_name>
    <description>Fiber blocking is calculated in different commercially available dialyzers using different anticoagulation strategies</description>
    <arm_group_label>Evodial_HD_no anticoagulation</arm_group_label>
    <arm_group_label>Evodial_HD_no anticoagulation_albuprime</arm_group_label>
    <arm_group_label>FX800_HD_1/1anticoagulation</arm_group_label>
    <arm_group_label>FX800_HD_1/2anticoagulation</arm_group_label>
    <arm_group_label>FX800_HD_1/2anticoagulation_albuprime</arm_group_label>
    <arm_group_label>FX800_postHDF_1/1anticoagulation</arm_group_label>
    <arm_group_label>FX800_postHDF_1/2anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_1/1anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_1/2anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_1/4anticoagulation</arm_group_label>
    <arm_group_label>Solacea_HD_no anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_1/1anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_1/2anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_1/4anticoagulation</arm_group_label>
    <arm_group_label>Solacea_postHDF_no anticoagulation</arm_group_label>
    <arm_group_label>Solacea_preHDF_1/4anticoagulation</arm_group_label>
    <arm_group_label>Solacea_preHDF_no anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>preparation of dialyzer</intervention_name>
    <description>Fiber blocking is calculated in different commercially available dialyzers either preprimed with Albumin or not</description>
    <arm_group_label>Evodial_HD_no anticoagulation_albuprime</arm_group_label>
    <arm_group_label>FX800_HD_1/2anticoagulation</arm_group_label>
    <arm_group_label>FX800_HD_1/2anticoagulation_albuprime</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  experienced stable dialysis sessions during the last 4 weeks&#xD;
&#xD;
          -  double needle/lumen well-functioning vascular access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known coagulation disorder&#xD;
&#xD;
          -  active inflammation&#xD;
&#xD;
          -  malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ghent University Hospital - Nephrology</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <results_reference>
    <citation>Vanommeslaeghe F, Van Biesen W, Dierick M, Boone M, Dhondt A, Eloot S. Micro-computed tomography for the quantification of blocked fibers in hemodialyzers. Sci Rep. 2018 Feb 8;8(1):2677. doi: 10.1038/s41598-018-20898-w.</citation>
    <PMID>29422614</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemodialyzer</keyword>
  <keyword>fibre clotting</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

